Cargando…

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers

BACKGROUND: The application of genomic technologies to patient tumor samples identified groups of signaling pathways which acquire activating mutations. Some cancers are dependent on these mutations and the aberrant proteins resulting from these mutations can be targeted by novel drugs which can era...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milewska, Malgorzata, Cremona, Mattia, Morgan, Clare, O’Shea, John, Carr, Aoife, Vellanki, Sri HariKrishna, Hopkins, Ann M., Toomey, Sinead, Madden, Stephen F., Hennessy, Bryan T., Eustace, Alex J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784557/ https://www.ncbi.nlm.nih.gov/pubmed/29383036 http://dx.doi.org/10.1177/1758834017746040

Ejemplares similares

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
por: Coté, Damien, et al.
Publicado: (2018)

A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib
por: O’Shea, John, et al.
Publicado: (2017)

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer
por: Toomey, Sinead, et al.
Publicado: (2016)

Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer
por: Elster, Naomi, et al.
Publicado: (2018)

Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer
por: Lee, Cha Len, et al.
Publicado: (2023)

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies
por: Toomey, Sinead, et al.
Publicado: (2017)

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
por: Mezynski, M. Janusz, et al.
Publicado: (2021)

Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)
por: Richards, Cathy E., et al.
Publicado: (2023)

BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors
por: Cremona, Mattia, et al.
Publicado: (2022)

Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples
por: Toomey, Sinead, et al.
Publicado: (2020)

Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro
por: Aslan, Ozlem, et al.
Publicado: (2018)

Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1
por: Cruz, Rodrigo G. B., et al.
Publicado: (2021)

Fusobacterium nucleatum: caution with interpreting historical patient sample cohort
por: Johnstone, Kate L. F., et al.
Publicado: (2021)

Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings
por: Leech, Astrid O., et al.
Publicado: (2018)

A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin
por: Mukherjee, Nupur, et al.
Publicado: (2022)

Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer
por: Kennedy, Sean P., et al.
Publicado: (2020)

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
por: Cosgrove, Nicola, et al.
Publicado: (2023)

Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2020)

Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
por: Kalachand, Roshni D., et al.
Publicado: (2020)

Functional Antagonism of Junctional Adhesion Molecule-A (JAM-A), Overexpressed in Breast Ductal Carcinoma In Situ (DCIS), Reduces HER2-Positive Tumor Progression
por: Smith, Yvonne E., et al.
Publicado: (2022)

COVID-19 contamination of high-touch surfaces in the public domain
por: Hennessy, Niall T., et al.
Publicado: (2022)

Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development
por: Madden, Stephen F., et al.
Publicado: (2022)

Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy
por: Gaynor, Nicola, et al.
Publicado: (2023)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
por: Dowling, Gavin P., et al.
Publicado: (2023)

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling
por: Wandinger, Sebastian K., et al.
Publicado: (2016)

Patient perceptions of the challenges of recruitment to a renal randomised trial registry: a pilot questionnaire-based study
por: Murphy, Ellen, et al.
Publicado: (2021)

Tumour Genome Characterization of a Rare Case of Pulmonary Enteric Adenocarcinoma and Prior Colon Adenocarcinoma
por: Smyth, Robert J., et al.
Publicado: (2021)

Social isolation due to the COVID-19 pandemic has led to worse outcomes in females with inflammatory arthritis
por: Maguire, Sinead, et al.
Publicado: (2020)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

NRG1/ERBB3/ERBB2 Axis Triggers Anchorage-Independent Growth of Basal-like/Triple-Negative Breast Cancer Cells
por: Miano, Carmen, et al.
Publicado: (2022)

Overexpression of the microRNA miR-433 promotes resistance to paclitaxel through the induction of cellular senescence in ovarian cancer cells
por: Weiner-Gorzel, Karolina, et al.
Publicado: (2015)

ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report
por: Minuto, Michele, et al.
Publicado: (2018)

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
por: Kancha, Rama Krishna, et al.
Publicado: (2011)

ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers
por: Mooz, Juliane, et al.
Publicado: (2022)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2
por: Dong, H, et al.
Publicado: (2017)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017)

Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies
por: Miano, Carmen, et al.
Publicado: (2022)

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
por: Choi, Byung-Kwon, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dtkbv4mq3etm35gvdi4s6q4utg